THE INVESTOR

메뉴열기
[THE INVESTOR] Shares of Hanmi Pharmaceutical dropped sharply on Feb. 19 after Eli Lilly decided to stop clinical trials of an autoimmune treatment licensed from the Korean firm in patients with rheumatoid arthritis. On Feb. 14, Hanmi announced that Eli Lilly will discontinue the clinical study for HM71224, an experimental Bruton’s tyrosine kinase inhibitor for the treatment of rheumatoid arthritis because it is “unlikely to meet the primary efficacy endpoint in the ongoing phase 2 trials.”Hanmi
  • KOSPI 2442.82 ▲20.99
  • KOSDAQ 875.81 ▲27.78
  • USD/KRW 1135.50 ▲2.70
  • CNH/KRW 164.33 ▲0.26
  • DUBAI 410548.5
  • TB(3Year) 2.302
이전 다음
최상단으로
Herald Corporation|CEO : Kwon Chung Won
Chief Privacy Officer & Juvenile Protection Manager : Shin Chang Hoon
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0615|Business info
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.